Literature DB >> 2722208

Production and characterization of murine monoclonal antibody to human alpha-lactalbumin.

E T Thean1, B H Toh.   

Abstract

Human alpha-lactalbumin (alpha-LA), a milk protein normally produced by, and restricted to, functionally differentiated breast epithelial cells has been shown immunohistochemically to be a good marker for breast cancer. Antibodies with specificity only for human alpha-LA have not previously been reported. The present study documents the production and characterization of an IgG1 murine monoclonal antibody with specificity restricted only to human alpha-LA. This monoclonal antibody, designated ET-1, was purified by affinity chromatography using human alpha-LA. Specificity of ET-1 for human alpha-LA was established by enzyme linked immunosorbent assay (ELISA), absorption studies, immunoprecipitation and by immunoblotting. ET-1 binds to human alpha-LA with a KD of 7.41 x 10(-8) mol/l and does not cross-react with bovine alpha-LA. This unique reactivity of ET-1, which is not inherently shared by polyclonal antisera, should enable the antibody to be used for the development of a sensitive immunoassay for circulating human alpha-LA.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2722208     DOI: 10.1038/icb.1989.5

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  3 in total

1.  Immunization with gastric H+/K(+)-ATPase induces a reversible autoimmune gastritis.

Authors:  K J Scarff; J M Pettitt; I R Van Driel; P A Gleeson; B H Toh
Journal:  Immunology       Date:  1997-09       Impact factor: 7.397

2.  Preclinical evaluation of the novel monoclonal antibody H6-11 for prostate cancer imaging.

Authors:  Hongjun Jin; Mai Xu; Prashanth K Padakanti; Yongjian Liu; Suzanne Lapi; Zhude Tu
Journal:  Mol Pharm       Date:  2013-09-03       Impact factor: 4.939

3.  Serum human alpha-lactalbumin as a marker for breast cancer.

Authors:  E T Thean; B H Toh
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.